This review examined eight recent, individually attributed price targets. They cluster between $48 and $65 and produce an arithmetic mean of roughly $53. The specific targets include $51 from Truist, $55 from Mizuho, $48 from Barclays (Equal Weight, initiated), $48 from Citi (Neutral), $54 from Bernstein, $48 from Wells Fargo (Equal Weight), $65 from Oppenheimer, and $56 from BTIG. The mean of roughly $53 is used here as the central target, rounded for readability.
For context, broader data aggregators report a wider range of roughly $44 to $85, with a blended average closer to $59 across roughly 30-plus analysts. The dispersion is striking: cautious analysts such as Citi and Wells Fargo argue the recovery path is opaque, while more constructive voices such as Oppenheimer see value after the reset. Citi downgraded the shares to Neutral in mid-September, citing "uncertain road ahead," while Barclays initiated coverage at Equal Weight. Several firms have cut targets repeatedly through 2026 as growth estimates came down. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
At approximately $45.70, a move to $53 implies about 16% upside — a modest, achievable-in-theory distance, but one that runs against a powerful downward trend. The shares have fallen more than 50% from their 52-week high, with revenue growth decelerating from roughly 20% to the mid-single digits as management cut 2026 organic growth guidance to 5%–6% and adjusted EPS guidance to $3.28–$3.32.
The path toward $53 would most likely require investors to look through a "lost year" toward 2027 and 2028, when the company plans seven product launches into a combined addressable market of more than $25 billion, alongside the closing of its roughly $14.5 billion Penumbra (PEN) acquisition.
Despite the reset, roughly three-quarters of Boston Scientific's revenue base was still growing about 6% through mid-2026. The company is pressing ahead with a restructuring program and buybacks, and its diversified portfolio — spanning cardiology, endoscopy, urology, and neuromodulation — provides multiple potential recovery levers. The Penumbra deal would add mechanical thrombectomy and neurovascular capabilities. A stabilization in WATCHMAN and electrophysiology trends, plus a clean 2027 outlook, could prompt analysts to lift targets from their currently depressed levels.
The obstacles are substantial. Newly published clinical evidence on atrial fibrillation stroke risk has changed WATCHMAN referral patterns, and the U.S. pulsed field ablation market is now roughly 80% penetrated, leaving limited room for FARAPULSE to offset competitor share gains. Urology and cardiac rhythm management have also underperformed. A cyberattack disclosed in late August disrupted manufacturing and order processing, and in September the company said it no longer expected to meet its 2026 sales and profit forecasts. Management has signaled limited adjusted EPS growth in 2027, and multiple recalls have added regulatory scrutiny.
Technically, the picture remains bearish. The stock trades below its 90-day and 200-day simple moving averages and sits just above a 52-week low near $42–$43. That zone is the critical support level to watch. On the upside, the $48–$55 area — where several recent analyst targets and prior breakdown levels converge — represents the first meaningful resistance level. The old highs near $105 are far removed from the current structure.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. The most immediate catalyst is the third-quarter earnings report on October 28, when the company is expected to provide an updated outlook following the cyberattack. Investors should monitor WATCHMAN and electrophysiology trends, the status of the Penumbra deal, restructuring progress, any further guidance revisions, and whether cautious analysts such as Citi and Wells Fargo begin to reverse their downgrades. From what I see, this upcoming report will be key to clarifying the near-term trajectory.
The $53 target — the mean of eight recent analyst targets ranging from $48 to $65 — implies a modest 16% gain from the current price near $45.70, yet the road is far from straightforward. The bull case rests on a diversified portfolio, cost savings, buybacks, and a 2028 pipeline, while the bear case centers on WATCHMAN and electrophysiology weakness, cyberattack fallout, and an uncertain 2027. With targets split from $48 to $85 and key franchise trends still unresolved, reaching $53 depends above all on whether the company can show that its growth reset is stabilizing rather than deepening. No outcome is guaranteed.
In my own analysis workflow, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to gain an additional layer of insight on names experiencing volatility like this one. The tool continuously scans thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals driven by technical behavior and market shifts. For traders looking to complement traditional research with systematic signals, it offers a practical way to track evolving trends without replacing core fundamental work.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 20 of the 33 cases the stock fell afterwards. This puts the odds of success at 61%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 50 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 26 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
BSX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BSX crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 201 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. BSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of medical devices
Industry MedicalNursingServices